Concepedia

Gerson Peltz

GP

25

Publications

3.3K

Citations

18

H-Index

2006

Active since

Affiliations

Pfizer (United States)(Current)

Peter MacCallum Cancer Centre

Massachusetts General Hospital

Sarah Cannon

Tennessee Oncology

Gerson Peltz is an author at Pfizer (United States) specializing in medicine, radiation oncology, and pathology.

Top concepts

Publications per year

2006–2023

25

Publications

25

First-Line Lorlatinib or Crizotinib in Advanced <i>ALK</i> -Positive Lung Cancer

Alice T. Shaw, Todd M. Bauer, Filippo de Marinis et al. · New England Journal of Medicine · 2020 · 1K citations · Full text

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study

Benjamin Solomon, Benjamin Besse, Todd M. Bauer et al. · The Lancet Oncology · 2018 · 772 citations

, , +6

Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial

Alice T. Shaw, Benjamin Solomon, Rita Chiari et al. · The Lancet Oncology · 2019 · 347 citations

, , +4

The role of fat mass index in determining obesity

Gerson Peltz, María Teresa Holguín Aguirre, Maureen Sanderson et al. · American Journal of Human Biology · 2010 · 191 citations

Clinical Management of Adverse Events Associated with Lorlatinib

Todd M. Bauer, Enriqueta Felip, Benjamin Solomon et al. · The Oncologist · 2019 · 157 citations · Full text

Rows per page

1–5 of 25